KeystoneBio
KeystoneBio provides AI-powered market research agents that automate complex value assessments and deal analysis for biotech companies. The platform analyzes public data on clinical trials, pharma dealmaking, and patient journeys to help users estimate program value and identify validation pathways. Its algorithms perform at 95-100% accuracy against human expert benchmarks before new disease area capabilities are released.
- Data & Analytics
- AI Agents
- Artificial Intelligence
- Software Only
Funding
Funding not disclosed
Founders
Founder details are not available yet.
Product
Problem
Biotech companies face data overload when assessing the market potential of their drug candidates, struggling to identify the right validation pathways, deal benchmarks, and value indicators from vast amounts of public information. Manual market analysis is time-consuming, error-prone, and often misses critical patterns in pharma dealmaking and patient journey data.
Solution
KeystoneBio provides AI-powered market research agents that automate complex value assessments and deal analysis for biotech companies. The platform analyzes publicly available data on clinical trials, pharma dealmaking patterns, and patient journeys to help users understand validation pathways and estimate short- and long-term program value. Users can prompt the system directly to generate precise, visually compelling reports that illustrate where their program fits in the competitive landscape and how it is differentiated. The platform pinpoints data that led to business development deals and tracks deal outcomes at each stage of development, enabling evidence-based strategic decisions.
Target Audience
Primary customers are biotech companies and drug developers who need to assess the market value of their therapeutic programs, understand competitor deal landscapes, and identify optimal validation and commercialization pathways.
Features
- AI agents that automate complex value assessments and identify deal opportunities
- Analysis of publicly available data on pharma dealmaking, including specific deal terms and outcomes by development stage
- Patient journey modeling that estimates peak revenue potential by identifying market share and positioning
- Natural language prompting to generate customized, visually compelling reports
- Algorithms performing at 95-100% accuracy against human expert benchmarks before new disease area release
- Current coverage of metabolic disorders with neurology next, followed by inflammation/immunology and oncology